The Financial

BASAGLAR (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...
Monthly Prescribing Reference

Basaglar Now Available for Type 1, Type 2 Diabetes

Eli Lilly and Boehringer Ingelheim announced the launch of Basaglar (insulin glargine injection) for use to control high blood sugar in children and adults with type 1 diabetes and adults with type 2 ...
Monthly Prescribing Reference

Basaglar Approved for Type 1, 2 Diabetes Mellitus

FDA Issues Complete Response Letter for Diabetes Drug The FDA has approved Basaglar (insulin glargine; Eli Lilly and Boehringer Ingelheim) injection to improve glycemic control in pediatric patients ...
FiercePharma

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...